
# **Response-adapted treatment with mosunetuzumab with or without obinutuzumab and** polatuzumab vedotin in treatment naïve follicular and marginal zone lymphoma: interim results and PhasED-Seq MRD analysis

Ryan C. Lynch<sup>1</sup>, Christina Poh<sup>1</sup>, Mazyar Shadman<sup>1</sup>, Brian G. Till<sup>1</sup>, Chaitra Ujjani<sup>1</sup>, Wengyang Di<sup>1</sup>, Vikram Raghunathan<sup>1</sup>, Stephen D. Smith<sup>1</sup>, David Maloney<sup>1</sup>, Daria Gausman<sup>1</sup>, Heather Rasmussen<sup>1</sup>, David A Russler-Germain<sup>2</sup>, Todd A Fehniger<sup>2</sup>, Hayley Warsinske<sup>3</sup>, Sierra Stowell<sup>3</sup>, David M. Kurtz<sup>3</sup>, Jenna Voutsinas<sup>1</sup>, Ajay K. Gopal<sup>1</sup>

<sup>1</sup>Fred Hutch Cancer Center, Seattle, WA, <sup>2</sup>Washington University School of Medicine, Saint Louis, MO, <sup>3</sup>Foresight Diagnostics, Boulder, CO

# Background

- Mosunetuzumab (mosun) is a CD3:CD20 bispecific antibody FDA-approved for R/R follicular lymphoma after two prior lines
- Outpatient fixed-duration dosing yields durable remissions in ~50% of patients<sup>1</sup>.
- We hypothesized that mosun would be even more active in patients without prior lymphotoxic chemotherapy<sup>2,3</sup>.
- There is limited data utilizing ultra-sensitive MRD testing (PhasED-Seq)<sup>4</sup> in untreated FL, and no current data in any setting utilizing this technology in patients treated with bispecific antibodies



Correlation of results with


# **Results: Safety**

# Demographics

Patient Characteristic	N = 38
Age, median (range)	59 (36- 83)
Baseline disease characteristics, n (%)	)
Stage 3 or 4 at Diagnosis, n (%)	36 (95%)
Histology	
Follicular lymphoma, grade 1-2	27 (71%)
Follicular lymphoma, grade 3a	7 (18%)
Marginal zone lymphoma	4 (11%)
B symptoms	5 (13%)
Extranodal disease	20 (53%)
Elevated LDH	6 (16%)
FLIPI 3-5 (FL only)	12 (35%)
Indications for treatment (can have more than 1)	
Symptomatic disease	30 (79%)
Threatened organ function	4 (11%)
Cytopenias	0 (0%)
Steady progression	11 (29%)
Bulk > 7 cm	13 (34%)
Hepatomegaly	0 (0%)
Splenomegaly	4 (11%)


# Grade 3-4 AEs

CTCAE Category	Grade 3-4
Neutropenia	4 (11%)
ALT Elevation	2 (5%)
Hypertension	2 (5%)
Abdominal pain	1 (3%)
Diarrhea	1 (3%)
Edema	1 (3%)
Hypertryglyceridemia	1 (3%)
Lung infection	1 (3%)
Malabsorption	1 (3%)
Syncope	1 (3%)
Thrombocytopenia	1 (3%)
Zoster	1 (3%)
Zoster	1 (3%)



10 (26%) patients with mosun delay

- Two patients with mulitple delays
- Infection, Neutropenia, Bone pain • Infection: 5
- Neutropenia: 4
- ALT elevation, hyperglycemia: 1 One patient permanently discontinued mosun after C1 due to persistent G1 CRS and G3 ALT elevation, subsequent PET in CR 8 (21%) patients required additional steroid pre-meds beyond C2 No patient required tocilizumab
  - No G3+ AEs experienced in those in Part B
  - Infections were common (17, 45%), but only one patient experienced G3+ infection • COVID-19: 4, 11%, All
  - G2 with no hospitalization • Liver toxicity uncommon
  - ALT ↑: Any 15 (39%)
  - AST ↑: Any 6 (16%)
  - Bili ↑: Any 6 (16%)



- vedotin

# Conclusion

- Fixed-duration mosun monotherapy achieves a high CR rate in untreated pts with follicular and marginal zone lymphoma • No G2+ CRS and no ICANS of any grade. • Injection site reactions and headaches were common but
- reversible.
- Most patients had detectable baseline ctDNA, and most cleared with 8 cycles of mosun monotherapy Acknowledgements
- We acknowledge our UW Medical Oncology Heme Malignancy research team, IFLI, Washington University in STL, our clinical support staff, and our PATIENTS. **References** 1: Budde LE et al. Blood 2021, 2: Marcus R et al. NEJM 2017, 3: Phillips T et al. ASH 2016, 4: Kurtz et al. Nat Biotech 2022 5: Cheson BD et al. JCO 2014



# UWMedicine